Our Website Uses Cookies 


We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.


For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Advises ChemGen Corp. in Acquisition By Eli Lilly

January 24, 2012

WASHINGTON, DC, January 24, 2012 — Covington & Burling LLP represented ChemGen Corp. in its definitive merger agreement with Eli Lilly and Company. Upon closing of the transaction, ChemGen will become a wholly-owned subsidiary of Eli Lilly and an operating unit of Elanco, the animal health division of Eli Lilly.

ChemGen, headquartered in Gaithersburg, Maryland, is a privately held bioscience company specializing in the development and commercialization of innovative feed enzyme products that improve the efficiency of poultry, egg and meat production in the animal health industry.

The transaction is expected to close in the first quarter of 2012.

The Washington-based Covington team was led by corporate partner Doug Gibson and corporate associate Scott Roades, with assistance from Leah Graham and Chris Hartsfield*. Also advising on the transaction were Mike Francese and Kathryn Johnson (employee benefits), Rob Heller and Sarah Burnham (tax), Heather Haberl (real estate), Thomas Hogan (environmental), and James Dean and Henry Liu (antitrust).

*Not yet admitted to practice.

Share this article: